Cardiology, Surgery. Company has developed a pain-free, implantable pace-setting device for maintaining a normal cardiac rhythm in patient’s suffering from cardiac arrhythmias where aberrant excitability in the heart causes irregular heartbeats, which can be fatal. The device functions by delivering a low-energy shock to the heart at particular specifications thereby serving as a pacemaker, much like the hearts own biological pacemaker, thereby restoring and maintaining normal cardiac rhythm. Atrial fibrillation is the leading cause of hospitalization for arrhythmia in the U.S., affecting approximately 2.5 million people. Atrial flutter is another type of arrhythmia that occurs less frequently and may evolve into atrial fibrillation. The company anticipates international commercialization of the device in four years and U.S. commercialization in six years. Founded: 2008.